Chinese Center for Disease Control and Prevention

Phase I Clinical Trial of AIM mRNA COVID-19 Vaccine (LVRNA009) Won the Praise of the Industry for High Safety and Well Tolerance

Retrieved on: 
Wednesday, January 12, 2022 - 1:26am

Safety data on the phase I clinical trial was released by Director Chen Guiling of Phase I Clinical Trial Laboratory of Shulan (Hangzhou) Hospital, and the results indicated high safety and well toleration.

Key Points: 
  • Safety data on the phase I clinical trial was released by Director Chen Guiling of Phase I Clinical Trial Laboratory of Shulan (Hangzhou) Hospital, and the results indicated high safety and well toleration.
  • Compared to the phase I clinical trial results of similar products, it demonstrated excellent safety and immunogenicity.
  • At present, the phase I clinical trials of all 3 China's mRNA vaccines are carried out at the Phase I Clinical Trial Laboratory of Shulan (Hangzhou) Hospital, among which the first mRNA vaccine is already under phase III clinical trial overseas.
  • At the meeting, top-notch experts acclaimed the phase I results of the mRNA COVID-19 vaccine (LVRNA009) of AIM Vaccine.

New Research Demonstrates Synexis® DHP™ Technology Eliminates >99.99% SARS-CoV-2 Delta Variant In Air

Retrieved on: 
Thursday, December 9, 2021 - 12:35pm

To determine if DHP Technology was efficacious against SARS-CoV-2 Delta variant viral contamination, scientists at Innovative Bioanalysis BSL3 laboratory conducted tests in a 20' x 8' x 8' chamber (approximate total volume of 1280 ft3).

Key Points: 
  • To determine if DHP Technology was efficacious against SARS-CoV-2 Delta variant viral contamination, scientists at Innovative Bioanalysis BSL3 laboratory conducted tests in a 20' x 8' x 8' chamber (approximate total volume of 1280 ft3).
  • Air samples were pulled from the room, analyzed and compared to controls (in a similar room not exposed to DHP) to determine whether DHP Technology inactivates the SARS-CoV-2 Delta variant.
  • "These results show DHP significantly cleans the air of the Delta variant virus in a controlled third-party real world size chamber.
  • This industry-leading research builds on the growing body of evidence showing DHP is effective at reducing bacteria, mold and viruses, including the SARS-CoV-2 Delta variant that continues to cause COVID-19."

Cocrystal Pharma’s SARS-CoV-2 Main Protease Inhibitors Demonstrate Pan-viral Activity against Human Common Coronaviruses, Noroviruses, Rhinoviruses, and Enteroviruses

Retrieved on: 
Monday, November 8, 2021 - 1:00pm

These protease inhibitors were discovered using the companys proprietary structure-based drug discovery technology and are currently being advanced by Cocrystal toward clinical development to combat SARS-CoV-2 and its variants.

Key Points: 
  • These protease inhibitors were discovered using the companys proprietary structure-based drug discovery technology and are currently being advanced by Cocrystal toward clinical development to combat SARS-CoV-2 and its variants.
  • Our current focus is on advancing these SARS-CoV-2 main protease inhibitors toward clinical development as a potential oral treatment for patients with COVID-19, he added.
  • We now have additional opportunities with these same protease inhibitors for future programs that target other areas of high unmet medical need.
  • Common human coronaviruses, not to be confused with SARS-CoV-2, usually cause mild to moderate upper-respiratory tract illnesses, like the common cold.

BioVaxys Files US Patent Application for Pan-Sarbecovirus Vaccine

Retrieved on: 
Wednesday, October 20, 2021 - 1:03pm

Sarbecoviruses, such as SARS-CoV-1 and SARS-CoV-2, all bind to the ACE2 receptor, which makes them highly transmissible.

Key Points: 
  • Sarbecoviruses, such as SARS-CoV-1 and SARS-CoV-2, all bind to the ACE2 receptor, which makes them highly transmissible.
  • For greater certainty, BioVaxys is not making any express or implied claims that it has the ability to treat the SAR-CoV-2 virus at this time.
  • ( www.biovaxys.com ) is a British Columbia-registered, clinical stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics.
  • BioVaxys has multiple issued US patents and pending patent applications related to its cancer vaccine, and pending patent applications for its SARS-CoV-2 (Covid-19) vaccine and diagnostic technologies.

BioVaxys Files US Patent Application for Pan-Sarbecovirus Vaccine

Retrieved on: 
Wednesday, October 20, 2021 - 1:00pm

Sarbecoviruses, such as SARS-CoV-1 and SARS-CoV-2, all bind to the ACE2 receptor, which makes them highly transmissible.

Key Points: 
  • Sarbecoviruses, such as SARS-CoV-1 and SARS-CoV-2, all bind to the ACE2 receptor, which makes them highly transmissible.
  • For greater certainty, BioVaxys is not making any express or implied claims that it has the ability to treat the SAR-CoV-2 virus at this time.
  • ( www.biovaxys.com ) is a British Columbia-registered, clinical stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics.
  • BioVaxys has multiple issued US patents and pending patent applications related to its cancer vaccine, and pending patent applications for its SARS-CoV-2 (Covid-19) vaccine and diagnostic technologies.

Global Protein Supplements Market Size, Share & Trends Analysis Report 2021-2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 12, 2021 - 1:53pm

The "Global Protein Supplements Market Size, Share & Trends Analysis Report by Source (Animal-based, Plant-based), by Product (Powder, RTD), by Distribution Channel (Online Stores, DTC), by Application, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Protein Supplements Market Size, Share & Trends Analysis Report by Source (Animal-based, Plant-based), by Product (Powder, RTD), by Distribution Channel (Online Stores, DTC), by Application, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.
  • The global protein supplements market size is expected to reach USD 36.05 billion by 2028, expanding at a CAGR of 8.4%
    The growing number of fitness centers on account of rising consumer interest in health and wellness is expected to drive the market over the forecast period.
  • The manufacturers are primarily concentrated in the Europe and North America regions owing to the abundant availability of raw materials.
  • In February 2020, InnovoPro launched chickpea protein concentrate for the Ready-To-Drink (RTD) formula for vegan athletes.

Top World Leaders to Gather Online for 18th Annual Meeting of Science and Technology in Society forum (STS forum)

Retrieved on: 
Thursday, September 16, 2021 - 7:00am

The forum will host 20 sessions online this year. Some examples of the topics are "Global Pandemic--Lessons Learned and Forecast," "Green Recovery for Sustainable Society," "Disruptive Technologies for Industries," "The Second Quantum Revolution and Society," "Lights and Shadows of Digital Economy," and "Path Toward Net-Zero Emission."

Key Points: 
  • TOKYO, Sept. 16, 2021 /PRNewswire/ -- The STS forum is holding its 18th Annual Meeting from October 2 to 5, 2021.
  • World leaders, including professional scientists, policymakers and business leaders, will gather online to discuss the pressing science and technology issues the world is facing and to build an international network.
  • The forum will host 20 sessions online this year.
  • Some examples of the topics are "Global Pandemic--Lessons Learned and Forecast," "Green Recovery for Sustainable Society," "Disruptive Technologies for Industries," "The Second Quantum Revolution and Society," "Lights and Shadows of Digital Economy," and "Path Toward Net-Zero Emission."

Top World Leaders to Gather Online for 18th Annual Meeting of Science and Technology in Society forum (STS forum)

Retrieved on: 
Thursday, September 16, 2021 - 7:00am

TOKYO, Sept. 16, 2021 /PRNewswire/ -- The STS forum is holding its 18th Annual Meeting from October 2 to 5, 2021. World leaders, including professional scientists, policymakers and business leaders, will gather online to discuss the pressing science and technology issues the world is facing and to build an international network.

Key Points: 
  • - Meeting Set for October 2 to 5, 2021, Seeking Better Future of Humankind -
    TOKYO, Sept. 16, 2021 /PRNewswire/ -- The STS forum is holding its 18th Annual Meeting from October 2 to 5, 2021.
  • World leaders, including professional scientists, policymakers and business leaders, will gather online to discuss the pressing science and technology issues the world is facing and to build an international network.
  • The forum will host 20 sessions online this year.
  • Some examples of the topics are "Global Pandemic--Lessons Learned and Forecast," "Green Recovery for Sustainable Society," "Disruptive Technologies for Industries," "The Second Quantum Revolution and Society," "Lights and Shadows of Digital Economy," and "Path Toward Net-Zero Emission."

Quanterix Receives Label Expansion on Emergency Use Authorization for COVID Antigen Test

Retrieved on: 
Monday, September 13, 2021 - 10:42pm

The expanded label establishes this test as the first antigen test authorized for use with saliva samples.

Key Points: 
  • The expanded label establishes this test as the first antigen test authorized for use with saliva samples.
  • The test can be run on Quanterix Simoa HD-X Analyzer , a fully automated high-throughput immunoassay instrument.
  • We are pleased to receive this EUA label expansion on our antigen test and demonstrate another advance in the body of evidence supporting Simoas potential for asymptomatic, less-invasive clinical testing.
  • In addition to its EUA assay, Quanterix has commercialized a SARS-CoV-2 N Protein Antigen Advantage Assay.